We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Hematological Parameters Compared in Psoriasis Patients

By LabMedica International staff writers
Posted on 19 Oct 2021
Print article
Image: Psoriatic plaques, showing a silvery center surrounded by a reddened border (Photo courtesy of Jane Bianchi, BA)
Image: Psoriatic plaques, showing a silvery center surrounded by a reddened border (Photo courtesy of Jane Bianchi, BA)
Psoriasis is a chronic, immune-mediated disorder that can involve the skin and/or joints. Four clinical types of psoriasis are currently recognized: psoriasis vulgaris (PsV), pustular psoriasis (PP), erythrodermic psoriasis (PsE), and arthritic psoriasis (PsA).

Systemic inflammation plays an important role in the pathogenesis of psoriasis, and numerous inflammatory mediators have been implicated, including interleukins (e.g., IL-17, IL-1β), other cytokines and chemokines, and serum autoantibodies. However, there is an urgent need to identify better markers for the diagnosis and assessment of clinical severity and outcomes of psoriasis.

Dermatologists at the Peking Union Medical College (Beijing, China) carried out hospital-based cross-sectional retrospective study that included a total of 477 patients (328 males, 149 females; mean age 43.5 ± 14.3 years): 347 with psoriasis vulgaris (PsV), 37 with generalized pustular psoriasis (GPP), 45 with erythrodermic psoriasis (PsE), 25 with arthritic psoriasis (PsA) and 23 with mixed psoriasis, and 954 healthy control subjects (656 males, 298 females; mean age 43.5 ± 14.3 years).

Demographic, clinical, and laboratory data were obtained from electronic or handwritten medical records. The following parameters were extracted: white blood cell (WBC), neutrophil, lymphocyte, red blood cell (RBC), and platelet counts, and hemoglobin (Hb) levels. In addition, neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were calculated and the psoriasis area severity index (PASI) scoring system was used to assess the severity of PsV.

The investigators reported that compared with the healthy control group, patients with psoriasis had higher total white blood cell (WBC), neutrophil, platelet counts, neutrophil to lymphocyte ratio (NLR), and platelet to lymphocyte ratio (PLR), but lower hemoglobin (Hb) levels, lymphocyte and red blood cell (RBC) counts. NLR values in the PsV group were significantly lower than those in the GPP, PsE, and PsA groups, with GPP group being the highest. PLR values in the PsV group were significantly lower than those in the GPP, PsE, and PsA groups. There was no significant correlation between the psoriasis area severity index (PASI) score and either the NLR or PLR in the PsV group.

The authors concluded that their results highlight the significant differences in NLR and PLR among psoriasis patients. Neutrophil counts and NLR were significantly higher in psoriasis group compared with the control group, with the GPP group having the highest NLR. In addition, platelet counts and PLR are increased in psoriasis patients, especially in the most severe subtype. The study was published on September 26, 2021 in the journal BMC Immunology.

Related Links:
Peking Union Medical College

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.